JP2012527447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527447A5 JP2012527447A5 JP2012511409A JP2012511409A JP2012527447A5 JP 2012527447 A5 JP2012527447 A5 JP 2012527447A5 JP 2012511409 A JP2012511409 A JP 2012511409A JP 2012511409 A JP2012511409 A JP 2012511409A JP 2012527447 A5 JP2012527447 A5 JP 2012527447A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- liquid composition
- levodopa
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 9
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 5
- 229960004502 levodopa Drugs 0.000 claims 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 229960003337 entacapone Drugs 0.000 claims 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960004603 tolcapone Drugs 0.000 claims 2
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 150000001483 arginine derivatives Chemical class 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17951109P | 2009-05-19 | 2009-05-19 | |
| US61/179,511 | 2009-05-19 | ||
| PCT/IL2010/000400 WO2010134074A1 (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014221786A Division JP5921002B2 (ja) | 2009-05-19 | 2014-10-30 | ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012527447A JP2012527447A (ja) | 2012-11-08 |
| JP2012527447A5 true JP2012527447A5 (https=) | 2014-05-29 |
| JP5643297B2 JP5643297B2 (ja) | 2014-12-17 |
Family
ID=42320738
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511409A Active JP5643297B2 (ja) | 2009-05-19 | 2010-05-17 | ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物 |
| JP2014221786A Active JP5921002B2 (ja) | 2009-05-19 | 2014-10-30 | ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物 |
| JP2016078121A Active JP6157678B2 (ja) | 2009-05-19 | 2016-04-08 | ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014221786A Active JP5921002B2 (ja) | 2009-05-19 | 2014-10-30 | ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物 |
| JP2016078121A Active JP6157678B2 (ja) | 2009-05-19 | 2016-04-08 | ドーパデカルボキシラーゼ阻害剤の連続投与のための組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8193243B2 (https=) |
| EP (3) | EP3192500B1 (https=) |
| JP (3) | JP5643297B2 (https=) |
| KR (2) | KR101709904B1 (https=) |
| CN (2) | CN102438587B (https=) |
| AR (3) | AR078413A1 (https=) |
| AU (1) | AU2010250766B2 (https=) |
| BR (1) | BRPI1011031B8 (https=) |
| CA (1) | CA2761624C (https=) |
| CL (1) | CL2011002895A1 (https=) |
| CY (1) | CY1119495T1 (https=) |
| DK (2) | DK3192500T3 (https=) |
| ES (2) | ES2840748T3 (https=) |
| HR (2) | HRP20170805T1 (https=) |
| HU (2) | HUE052685T2 (https=) |
| IL (1) | IL216383A (https=) |
| LT (1) | LT2432454T (https=) |
| MX (2) | MX364974B (https=) |
| NZ (1) | NZ596963A (https=) |
| PL (2) | PL2432454T3 (https=) |
| PT (2) | PT2432454T (https=) |
| RU (3) | RU2559083C9 (https=) |
| SG (3) | SG176159A1 (https=) |
| SI (1) | SI2432454T1 (https=) |
| WO (1) | WO2010134074A1 (https=) |
| ZA (1) | ZA201109037B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN192600B (https=) * | 1996-10-18 | 2004-05-08 | Hoechst Celanese Corp | |
| PL2432454T3 (pl) * | 2009-05-19 | 2017-10-31 | Neuroderm Ltd | Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy |
| PT2640358T (pt) * | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
| NZ703341A (en) | 2012-06-05 | 2016-11-25 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| CN103845318A (zh) * | 2012-12-07 | 2014-06-11 | 天津市汉康医药生物技术有限公司 | 恩他卡朋分散片 |
| AU2014229127B2 (en) * | 2013-03-13 | 2018-04-05 | Neuroderm Ltd | Method for treatment of parkinson's disease |
| CN113384373B (zh) * | 2013-11-05 | 2022-10-21 | 辛纳吉勒公司 | 经由口腔进行连续药物递送的装置和方法 |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| DK3116475T3 (da) | 2014-03-13 | 2020-12-07 | Neuroderm Ltd | Dopa-decarboxylasehæmmersammensætninger |
| JP6622310B2 (ja) | 2014-09-04 | 2019-12-18 | ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
| RU2021103000A (ru) | 2014-10-21 | 2021-03-01 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| CN108495617A (zh) | 2015-11-24 | 2018-09-04 | 纽罗德姆有限公司 | 包含左旋多巴酰胺的药物组合物和其用途 |
| WO2017177262A1 (en) * | 2016-04-11 | 2017-10-19 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| US10064834B2 (en) | 2016-05-09 | 2018-09-04 | Texas Tech University System | Carbidopa for the treatment of cancer |
| CA3065990A1 (en) | 2017-06-05 | 2018-12-13 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
| US20230123806A1 (en) * | 2017-07-07 | 2023-04-20 | Neuroderm, Ltd. | Device for subcutaneous delivery of fluid medicament |
| BR112020017422A2 (pt) * | 2018-03-29 | 2020-12-22 | Avion Pharmaceuticals , Llc | Composição de dose fracionada de levodopa e uso |
| BR112021009353A2 (pt) | 2018-11-15 | 2021-11-23 | Abbvie Inc | Formulações farmacêuticas para administração subcutânea |
| US20220226269A1 (en) * | 2019-06-12 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| WO2022047298A1 (en) * | 2020-08-31 | 2022-03-03 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| KR20230124622A (ko) * | 2020-12-22 | 2023-08-25 | 암닐 파마슈티컬스 엘엘씨 | 레보도파 투여 요법 |
| US20250082595A1 (en) * | 2022-01-03 | 2025-03-13 | Neuroderm, Ltd. | Methods and compositions for treating parkinson’s disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769424A (en) * | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
| US3936495A (en) * | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (ja) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) * | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| DE252290T1 (de) * | 1986-06-10 | 1988-06-09 | Chiesi Farmaceutici S.P.A., Parma | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4684666A (en) * | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5350769A (en) * | 1990-10-30 | 1994-09-27 | Ss Pharmaceutical Co., Ltd. | Antiinflammatory gel preparation |
| US5877176A (en) * | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| GB9523833D0 (en) | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US6245917B1 (en) * | 1998-03-20 | 2001-06-12 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) * | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| CA2327285C (en) | 1998-05-15 | 2005-06-14 | Warner-Lambert Company | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| US6274168B1 (en) * | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2000054773A1 (en) | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) * | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) * | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) * | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| US6916813B2 (en) | 2001-12-10 | 2005-07-12 | Bristol-Myers Squibb Co. | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
| US20060159751A1 (en) * | 2002-04-11 | 2006-07-20 | Mona Gogia | Controlled release pharmaceutical compositions of carbidopa and levodopa |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| EP1551829B1 (de) | 2002-10-10 | 2010-04-07 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Neue verbindungen mit antibakterieller aktivität |
| BRPI0412735A (pt) * | 2003-07-18 | 2006-09-26 | Baxter Int | métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| US7589233B2 (en) * | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| DE602004031134D1 (de) * | 2003-08-29 | 2011-03-03 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| US20050053669A1 (en) | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| KR20060108692A (ko) * | 2003-10-31 | 2006-10-18 | 알자 코포레이션 | 메트포르민의 개선된 흡수를 위한 조성물 및 제형 |
| CN1901880A (zh) * | 2003-10-31 | 2007-01-24 | 阿尔扎公司 | 用于增加二甲双胍吸收的组合物和剂型 |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| WO2006037061A2 (en) * | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| WO2006043532A1 (ja) * | 2004-10-19 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | パーキンソン病治療剤 |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2007138086A1 (en) | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| JP5631734B2 (ja) * | 2007-04-06 | 2014-11-26 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 流体薬物を供給するためのシステム及び方法 |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| PL2432454T3 (pl) | 2009-05-19 | 2017-10-31 | Neuroderm Ltd | Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| TR201808178T4 (tr) | 2010-11-15 | 2018-07-23 | Neuroderm Ltd | Aktif ajanların transdermal dağıtımı için bileşimler. |
| PT2640358T (pt) | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
| WO2012079072A2 (en) | 2010-12-10 | 2012-06-14 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| AU2014229127B2 (en) | 2013-03-13 | 2018-04-05 | Neuroderm Ltd | Method for treatment of parkinson's disease |
| DK3116475T3 (da) | 2014-03-13 | 2020-12-07 | Neuroderm Ltd | Dopa-decarboxylasehæmmersammensætninger |
-
2010
- 2010-05-17 PL PL10725880T patent/PL2432454T3/pl unknown
- 2010-05-17 MX MX2015001674A patent/MX364974B/es unknown
- 2010-05-17 CN CN201080022208.3A patent/CN102438587B/zh active Active
- 2010-05-17 JP JP2012511409A patent/JP5643297B2/ja active Active
- 2010-05-17 CN CN201410800432.0A patent/CN104546700B/zh active Active
- 2010-05-17 SG SG2011085297A patent/SG176159A1/en unknown
- 2010-05-17 WO PCT/IL2010/000400 patent/WO2010134074A1/en not_active Ceased
- 2010-05-17 ES ES17158360T patent/ES2840748T3/es active Active
- 2010-05-17 EP EP17158360.2A patent/EP3192500B1/en active Active
- 2010-05-17 MX MX2011012315A patent/MX2011012315A/es active IP Right Grant
- 2010-05-17 PT PT107258808T patent/PT2432454T/pt unknown
- 2010-05-17 KR KR1020167019114A patent/KR101709904B1/ko active Active
- 2010-05-17 EP EP10725880.8A patent/EP2432454B1/en active Active
- 2010-05-17 HR HRP20170805TT patent/HRP20170805T1/hr unknown
- 2010-05-17 SG SG10201709016RA patent/SG10201709016RA/en unknown
- 2010-05-17 EP EP20197759.2A patent/EP3777839A1/en active Pending
- 2010-05-17 RU RU2011149976/15A patent/RU2559083C9/ru active
- 2010-05-17 NZ NZ596963A patent/NZ596963A/en not_active IP Right Cessation
- 2010-05-17 PT PT171583602T patent/PT3192500T/pt unknown
- 2010-05-17 BR BRPI1011031A patent/BRPI1011031B8/pt active IP Right Grant
- 2010-05-17 HU HUE17158360A patent/HUE052685T2/hu unknown
- 2010-05-17 DK DK17158360.2T patent/DK3192500T3/da active
- 2010-05-17 SG SG10201505101VA patent/SG10201505101VA/en unknown
- 2010-05-17 HU HUE10725880A patent/HUE033388T2/en unknown
- 2010-05-17 PL PL17158360T patent/PL3192500T3/pl unknown
- 2010-05-17 LT LTEP10725880.8T patent/LT2432454T/lt unknown
- 2010-05-17 AU AU2010250766A patent/AU2010250766B2/en active Active
- 2010-05-17 DK DK10725880.8T patent/DK2432454T3/en active
- 2010-05-17 US US12/781,357 patent/US8193243B2/en active Active
- 2010-05-17 CA CA2761624A patent/CA2761624C/en active Active
- 2010-05-17 RU RU2015115064A patent/RU2678839C2/ru active
- 2010-05-17 ES ES10725880.8T patent/ES2627655T3/es active Active
- 2010-05-17 SI SI201031466T patent/SI2432454T1/sl unknown
- 2010-05-17 KR KR1020117030315A patent/KR101641401B1/ko active Active
- 2010-05-19 AR ARP100101735A patent/AR078413A1/es not_active Application Discontinuation
- 2010-07-14 US US12/836,130 patent/US7863336B2/en active Active
- 2010-12-07 US US12/961,534 patent/US9101663B2/en active Active
-
2011
- 2011-11-15 IL IL216383A patent/IL216383A/en active IP Right Grant
- 2011-11-17 CL CL2011002895A patent/CL2011002895A1/es unknown
- 2011-12-08 ZA ZA2011/09037A patent/ZA201109037B/en unknown
-
2014
- 2014-05-13 US US14/276,235 patent/US9040590B2/en active Active
- 2014-05-13 US US14/276,211 patent/US9040589B2/en active Active
- 2014-10-30 JP JP2014221786A patent/JP5921002B2/ja active Active
-
2015
- 2015-07-01 US US14/789,214 patent/US9993451B2/en active Active
-
2016
- 2016-04-08 JP JP2016078121A patent/JP6157678B2/ja active Active
-
2017
- 2017-05-31 CY CY20171100573T patent/CY1119495T1/el unknown
-
2018
- 2018-05-30 US US15/992,979 patent/US20190125708A1/en not_active Abandoned
-
2019
- 2019-01-16 RU RU2019101159A patent/RU2019101159A/ru unknown
- 2019-03-28 AR ARP190100805A patent/AR117412A2/es unknown
- 2019-12-23 AR ARP190103847A patent/AR117502A2/es not_active Application Discontinuation
-
2020
- 2020-04-30 US US16/863,459 patent/US20210077442A1/en not_active Abandoned
- 2020-12-21 HR HRP20202038TT patent/HRP20202038T1/hr unknown
-
2022
- 2022-11-11 US US17/985,556 patent/US20230321019A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012527447A5 (https=) | ||
| HRP20170805T1 (hr) | Pripravak za kontinuiranu primjenu inhibiotra dopa dekarboksilaze | |
| NZ610911A (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same | |
| JP2016512230A5 (https=) | ||
| PH12019500517A1 (en) | Long-acting formulations of insulins | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| MX355742B (es) | Análogos deuterados del ácido 4-hidroxibutírico. | |
| WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| WO2012087976A3 (en) | Novel inhibitors of hepatitis c virus replication | |
| MX393128B (es) | Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas | |
| RU2015143112A (ru) | Способ лечения болезни паркинсона | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| BR112012018116A2 (pt) | "hormônios do crescimento com eficácia in vivo prolongada" | |
| JP2015502974A5 (https=) | ||
| MY174002A (en) | Combination theraphy for the treatment of diabetes | |
| JP2013542247A5 (https=) | ||
| EA201170018A1 (ru) | Разагилин для изменения течения болезни паркинсона | |
| NZ612717A (en) | Treatment of pain associated with dislocation of basal endometrium | |
| WO2011008054A3 (ko) | Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제 | |
| IN2014MN01892A (https=) | ||
| WO2013087654A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| JP2014532722A5 (https=) | ||
| WO2014085453A3 (en) | Small molecule lxr inverse agonists | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| UA102111C2 (uk) | Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі |